Tag: Phase III
-
Renalys Pharma Reports Positive Phase III Topline Results for Sparsentan in Japanese IgA Nephropathy Patients
Positive topline results in Japanese IgA nephropathy trial Renalys Pharma announced positive topline data from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy (IgAN). The trial enrolled 35 participants and was designed to assess the efficacy and safety of sparsentan, a dual-acting agent targeting both the endothelin and angiotensin receptor pathways,…
-
Sparsentan Phase III IgA Nephropathy in Japan: Positive Results
Groundbreaking Phase III topline results for Sparsentan in Japanese IgA nephropathy patients Renalys Pharma has announced positive topline results from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy. The trial, conducted in a cohort of 35 patients, focused on the primary endpoint of the percent change from baseline in the 24-hour…